Neumora Therapeutics, the neuroscience company launched last year in a bid to revitalize a field much of pharma abandoned, is raising a crossover round and considering filing for an IPO this summer, according to two sources with knowledge of the situation.
A Neumora spokesperson declined to comment, citing company policy “to not comment on financing plans or timelines.”
Create a display name to comment
This name will appear with your comment
